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Chapter 13
The Detection of Parvoviruses
Sean Doyle 
Abstract
Parvovirus B19 is a single-stranded DNA virus which causes severe disease in immunocompromised 
patients and foetal loss in pregnant women. It is classified as an Erythrovirus and this genus also 
comprises two related viral genotypes (so-called LaLi/A6 (genotype 2) and V9 (genotype 3)) which 
appear to be immunologically indistinguishable from Parvovirus B19. Serological and nucleic acid test 
(NAT) systems to detect Parvovirus B19-mediated infection are commercially available; however, some 
NAT systems are genotype-specific. International standard preparations of Parvovirus B19 IgG and 
DNA have been produced for assay standardisation purposes, and to ensure consistency of assay manu-
facture and performance. Immunological assays, such as B-cell ELISpot, T-cell stimulation, and cytokine 
detection can also be used to confirm exposure to Parvovirus B19. Immunohistochemical techniques, 
employing commercially available monoclonal antibodies, are used to localise the virus in infected tissue 
and Parvovirus B19 viral antigen can also be detected in serum and plasma using antigen-specific ELISA. 
NAT systems have also been described to detect newly identified parvoviruses such as human bocavirus 
(HBoV), PARV4, and PARV5, although absolute confirmation of clinical diseases associated with these 
agents is required. This chapter describes the current status of detection systems for all the aforemen-
tioned parvoviruses, with particular emphasis on Erythrovirus detection by serological, NAT, and immu-
nological approaches.
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Human parvovirus B19 (B19) is a non-enveloped, 5.5 kb 
single-stranded DNA virus (1). It belongs to the family 
Parvoviridae, sub-family Parvovirinae, genus Erythrovirus. 
Although initially identified as related genotypes of B19, so-called 
genotypes 2 (K71/LaLi/A6) and 3 (known as V9) have been 
reclassified as human parvovirus B19-A6, -LaLi, and -V9, respec-
tively (http://www.ncbi.nlm.nih.gov/ICTVdb/Ictv/fs_parvo.htm). 
1.  Introduction
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However, for clarity and familiarity, occasionally erythrovirus will 
be referred to as B19, genotype 2, and genotype 3 (or V9), 
respectively, throughout this chapter. These strains are immuno-
logically indistinguishable from B19, although they exhibit up to 
10–12% sequence divergence at the DNA level (2–4). B19 is a 
human pathogen, and infection is primarily a concern in both 
immunocompromised patients (e.g. cancer patients undergoing 
chemotherapy) and pregnant women, where B19 infection in the 
first two trimesters of pregnancy can lead to foetal loss (5). 
Emerging roles for B19 in the pathogenesis of certain kidney dis-
eases and myocardial damage are also emerging (6–9).
B19 transmission may be by respiratory droplets, vertical 
transmission of mother to foetus or via the receipt of B19-
contaminated blood or blood products (e.g. packed red cells, 
plasma, or platelets) (10). Upon infection with B19, high levels 
of virus appear in the circulatory system within days to weeks and 
may exceed 1013 viral particles/mL, followed by the appearance 
of virus-specific IgM and ultimately high-titre IgG (11). B19 is 
composed of two distinct viral proteins, namely VP1 (83 kDa) 
and VP2 (58 kDa), which form the 20 nm diameter viral capsid (1). 
These proteins are co-linearly encoded by the viral genome and 
are present in the viral capsid in the ratio 5:95 (VP1:VP2) (12). 
The recombinant expression of B19 VP1 and VP2 capsid proteins 
in the baculovirus expression system and their application in 
immunodiagnostic assays, to detect B19 exposure, have been 
extensively described (12, 13).
B19 DNA detection by PCR is now routinely used to com-
plement patient serology profile and viral DNA can be detected in 
serum, plasma, tissue extracts, and amniotic fluid (14). The latter 
has proven to be particularly useful for diagnosing materno-foetal 
B19 transmission (15). However, B19 viraemia may not be asso-
ciated with symptoms of infection, so in a blood donor context, 
an infected person could potentially donate blood within this 
time window, with obvious implications for blood or blood prod-
uct recipient exposure to the virus. As a consequence, many blood 
collection organisations and blood product manufacturers have 
implemented screening protocols to detect B19 DNA by PCR 
using minipool screening (i.e. making pools of aliquots of blood 
serum/plasma and screening same for B19 DNA) (16). Minipool, 
as opposed to individual specimen screening, is performed to 
reduce the cost associated with detection of B19 presence. 
However, despite the high sensitivity of detection associated with 
B19 detection via PCR, the associated cost, allied to (a) the 
potential high levels of viraemia leading to cross-contamination 
during screening and (b) the possibility of false negativity of 
detection during PCR due to sequence differences between geno-
types 1 and 3, means that alternative strategies need to be con-
sider for blood screening (17).
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Although a haemagglutination assay has been proposed to 
detect B19 in plasma (18, 19), this system is apparently too insen-
sitive to detect clinically relevant virus levels, moreover, B19 IgG 
presence in plasma may lead to virus occlusion and resultant false 
negativity of detection (2, 17). Consequently, two groups have 
proposed the use of an ELISA system, utilising anti-B19 IgG to 
detect the virus in human serum and plasma (17, 20). In addi-
tion, Corcoran et al. (17) have demonstrated that viral antigen 
detection can be enhanced by the use of a specialised diluent 
which significantly improves virus capture by the IgG[anti-B19] 
used in their immunoassay system. However, although both assays 
appear to work satisfactorily, the sensitivity of viral detection is 
limited to greater than 107 particles/mL. Thus, the potential to 
use emerging technologies (21) to improve the sensitivity of 
detection of B19 in plasma and serum merits consideration.
In order to standardise B19 serological (IgG) and molecular 
(DNA) diagnostic test systems and to aid B19 IgG and DNA 
assay performance, a number of WHO International Standards 
are available to both assay manufacturers and diagnostic laborato-
ries (22, 23).
A number of parvoviruses, distantly related to the erythro-
virus genus have been recently identified. Human bocavirus 
(HBoV), discovered in 2005, is classified as a member of the fam-
ily Parvoviridae (sub-family Parvovirinae, genus Bocavirus). Four 
HBoV proteins are likely to be encoded by the compact viral 
genome, namely NS1, NP-1, VP1, and VP2 with the latter two 
proteins co-linearly encoded as is the case for the Erythrovirus 
genus (24). HBoV infection appears to be strongly associated 
with acute respiratory tract infections (ARTI) with preliminary 
evidence emerging that the virus may also be a potential cause of 
gastroenteritis (25). Molecular and serological tests have been 
developed which allow the sensitive and specific detection of 
HBoV nucleic acid (26, 27) and HBoV IgG and/or IgM (28–30). 
Indeed, 17 PCR protocols for HBoV DNA detection, deploying 
a range of primer pairs and detection strategies, have recently 
been described (26). HBoV recombinant VP2 protein has been 
generated by two groups utilising the baculovirus expression sys-
tem (29, 30), while another group has expressed both HBoV 
VP1 and VP2 proteins in E. coli (28). At present, no cell culture 
systems for HBoV or virus-specific monoclonal antibody prepa-
rations are available to enable direct viral detection in vitro, 
although high-titre rabbit polyclonal antibodies have been pro-
duced which can immunoprecipitate HBoV virions from respira-
tory specimens (29).
A distinct parvovirus, termed PARV4 (parvovirus 4), was 
identified in plasma obtained from an intravenous drug user in 
2005 (31). This virus has been shown to contaminate approxi-
mately 5% of plasma pools, with PARV4 viral loads less than 
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106/mL (31). PARV4 is presently unclassified but is likely to 
form part of a new genus within the sub-family, Parvovirinae. In 
addition, a related viral genotype, termed either PARV4 genotype 
2 or PARV5 has also been identified (32). Although yet to be 
associated with any specific disease, the potential parenteral trans-
mission route of PARV4 has led to intensive investigations and it 
appears that tissue persistence of PARV4 is associated with paren-
teral exposure. Tissue persistence was initially thought to be asso-
ciated with immunosuppression or HIV/HCV co-infection; 
however, PARV4 has also been detected, at a low rate, in liver and 
bone marrow specimens from HIV- and HCV-negative individu-
als (33). No serological assay systems are presently available for 
PARV Ig detection.
This chapter will describe detailed serological, cellular, and 
molecular assay systems for B19 detection and introduce some of 
the nascent molecular, and serological assays for HBoV and 
PARV4 detection.
 1. WHO Parvovirus B19 IgG International Standard (01/602), 
contains 77 International units (IU) of B19 IgG per ampoule 
(NIBSC, Potters Bar, Herts, UK). http://www.nibsc.ac.uk. 
No B19 IgM standard is currently available.
 2. WHO Parvovirus B19 DNA International Standard (99/800), 
contains 5 × 105 IU of B19 DNA per vial (NIBSC, Potters 
Bar, Herts, UK). http://www.nibsc.ac.uk.
 3. WHO Parvovirus B19 DNA working Reagent (99/736), 
contains 1,000 IU of B19 DNA per mL (NIBSC, Potters 
Bar, Herts, UK). http://www.nibsc.ac.uk.
 4. Histopaque-1077 (Sigma-Aldrich, Dorset, UK).
 5. Nitrocellulose-lined plates (96 well) (Millipore, Bedford, 
MA, USA).
 6. Staphylococcus aureus cells (Cowan I strain) SAC (Calbiochem, 
Darmstadt, Germany).
 7. Interleukin-2 (IL-2) (Serotec Ltd, Oxford, UK).
 8. RPMI medium and foetal calf serum (http://www.invitrogen.
com).
 9. [3H]-Thymidine (GE Healthcare, Amersham, UK).
 10. Liquid scintillation fluid (GE Healthcare, Amersham, UK.).
 11. Streptavidin-conjugated alkaline phosphatase (Sigma-Aldrich, 
Dorset, UK).
2.  Materials
217The Detection of Parvoviruses
 12. Tetramethylbenzidine substrate (BioFX Laboratories Inc., 
Owings Mills, Maryland).
 13. Proteinase K (Sigma-Aldrich, Dorset, UK).
 14. Qiagen QiAmp Blood kit (Qiagen, Hilden, Germany).
 15. Ethidium bromide (Sigma-Aldrich, Dorset, UK).
 16. Polyclonal rabbit IgG [anti-parvovirus B19 VP2] (Code: 
B-0091) (DakoCytomation, Glostrup, Denmark).
 17. Taq polymerase and dNTP preparations (Promega, WI, 
USA).
 18. Betaine (Sigma-Aldrich, Dorset, UK).
Detection of B19 IgG and/or IgM is now routinely carried out 
either by commercially available ELISA, Western blot, or immu-
nofluorescent in vitro diagnostic tests (http://www.biotrin.
com/; http://www.ibl-america.com; http://www.mikrogen.de). 
Indeed, application of these validated and reliable test systems 
has removed much, if not all, of the variability associated with 
B19 antibody testing which was evident in the early 1990s. Two 
FDA-approved immunoassays are available to detect B19 IgM as 
a marker of recent infection (34), and IgG as a marker of past 
infection (35), respectively. These microplate immunoassays 
utilise B19-capsid VP2 and can detect genotype 1, 2, and 3 IgG 
(4, 36–39).
All commercial B19 IgG detection systems capture B19-
specific IgG onto an immobilised, recombinant B19 protein. 
After B19 IgG binding, removal of unwanted serum proteins and 
irrelevant IgG is achieved by a wash step. B19-specific IgG is then 
detected using either an enzyme- (generally horseradish peroxi-
dase) or fluorophore-labelled anti-human IgG antibody (Fig. 1). 
For microplate ELISA systems 3,3¢,5,5¢-tetramethylbenzidine 
(TMB) is now the substrate of choice. Precipitating substrates 
such as 3,3¢-diaminobenzidine (DAB) are used in Western blot 
assay systems. Detection of B19 IgM by ELISA systems from 
most commercial manufacturers is also enabled by the aforemen-
tioned assay format; however, IgG or rheumatoid factor (RF) 
removal is essential to avoid assay interference. IgM-capture 
(m-capture) technology is utilised in the FDA-approved B19 IgM 
assay system which appears to confer high assay specificity and 
avoids the requirement to use additional reagents such as anti-
human IgG or RF adsorbents (34).
Thus, accurate laboratory serodiagnosis of recent B19 infec-
tion or past exposure relies on testing serum or plasma specimens 
3.  Methods
3.1. Detection of B19 
IgG and IgM
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for either specific antibody reactivity against viral capsid proteins, 
VP2 or VP1, expressed in eukaryotic expression systems (e.g. 
baculovirus expression system) by ELISA. A specific advantage of 
the eukaryotic baculovirus expression system is its ability to enable 
the post-translational protein-folding necessary for the genera-
tion of soluble VP2 capsids (12). Unlike B19 VP2, VP1 does not 
appear to form soluble capsid structures; however, VP1 has been 
produced as a “conformationally intact” protein which has been 
shown to retain conformational epitopes present in the native 
virion (12, 13) (Fig. 1). Co-expression of VP1 and VP2 in eukary-
otic expression systems has been proposed to result in the forma-
tion of empty capsids, which are antigenically indistinguishable 
from native B19 virions.
Exposure to B19 in immunocompetent individuals results in 
the appearance of high-titre B19 IgM. The appearance of B19 
IgG then coincides with a diminishing IgM antibody response, 
and B19 IgG reactivity against conformational epitopes of VP1 
and VP2 persists post-infection. However, for both capsid pro-
teins, reactivity against linear epitopes disappears abruptly against 
VP2, but more slowly against VP1 (13, 40–42) – an observation 
which has significant consequences for diagnosis. Antibody reac-
tivity against linear VP2 epitopes, predominantly directed against 
a heptapeptide (amino acids 344–350; KYVTGIN) identified 
by analysis of acute-phase sera (40), usually disappears within 
6 months of B19 infection (41). This heptapeptide sequence is 
also present in V9 (genotype 3). Thus, detection of B19-specific 
IgG, directed against linear epitopes of VP2, may assist in timing 
B19 exposure to within a 6-month period. Although the  antibody 
response wanes against linear epitopes on B19 capsid proteins it 
persists against conformational epitopes of both capsid proteins. 
Indeed, this observation has been extended to a so-called second 
Fig. 1. Immunofluorescent detection of parvovirus B19 IgG using B19 VP1 recombinant baculovirus-infected Spodoptera 
frugiperda cell line (Sf9). (a) B19 IgG reactivity with B19 VP1 protein is detected using FITC-labelled murine anti-human 
IgG (intense green fluorescence against a background of red counterstained Sf9 cells). (b) No reactivity observed with B19 
IgG seronegative specimen. Courtesy of Biotrin (Dublin, Ireland).
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generation epitope type-specific (ETS) EIA which determines the 
ratio of B19 IgG reactivity against capsid VP2 and aforemen-
tioned heptapeptide (an ETS index). According to the authors, a 
cut-off value of 10 will distinguish between acute infection (ETS 
index £10) or past infection (ETS index ³10) (43).
The V9 VP1 and VP2 open reading frames have been cloned 
and expressed in the baculovirus expression system (37). These 
authors observed self-assembly of V9 VP1/VP2 and VP2 capsids 
into parvovirus-like particles (diameter approximately 23 nm). 
A panel of 270 clinical specimens were screened for the presence 
of V9 IgM and IgG antibodies in ELISA and showed 100% sero-
logic cross-reactivity between B19 and V9 when comparing V9 
VP2 capsids to the B19 VP2 ELISA. Thus, V9 and B19 antibody 
responses may be diagnosed equally well by ELISA using either 
V9 or B19 recombinant capsids as antigen source (37). Moreover, 
Heegaard et al. noted that most genetic variation between geno-
types 1 and 3 (Table 1) resulted in silent mutations resulting in 
96–97% identity at the protein sequence level.
Controversial data was presented in 2004 which suggested 
that enzyme immunoassays utilising B19 VP2 capsids derived 
from genotype 1 did not detect a subset of V9-derived IgG (36). 
This preliminary finding was based on the use of an unvalidated 
in-house IgG ELISA which used a V9 VP1 protein as a diagnos-
tic antigen. Candotti et al. (36) also noted that the small num-
bers of amino acid substitutions in VP1u and NS1 regions of 
genotype 3 strain, compared to genotype 1, did not modify 
Table 1 
Parvovirus nomenclature
Name Genotype Additional name
Parvovirus B19-Au 1 Parvovirus B19
Parvovirus B19-A6 2 K71, LaLi, A6
Parvovirus B19-V9 3 V9
Human Bocavirus – HBoV
PARV4 – –
PARV5 – PARV4, genotype 2
Parvoviruses belong to the family Parvoviridae (sub-family Parvovirinae, genus 
Erythrovirus). Genotypes of B19 (genotype 2 (K71/LaLi/A6) and 3 (V9) are now 
classified as human parvovirus B19-A6, -LaLi, and -V9, respectively (http://www.
ncbi.nlm.nih.gov/ICTVdb/Ictv/fs_parvo.htm). Parvovirus B19 has been officially 
classified as B19 virus but this nomenclature has failed to gain widespread use. A num-
ber of companies manufacture in vitro diagnostic tests, based on B19 capsid proteins, 
which detect human antibodies produced upon infection with each of the parvovirus 
B19 genotypes (1–3). HBoV falls within the genus Bocavirus and classification of 
PARV4 and 5 is outstanding
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protein hydrophilicity or antigenicity. This again underlines 
the fundamental identity and indistinguishable immunological 
nature of both B19 and V9-derived proteins. The findings of 
Candotti et al. relating to proposed differences between B19 and 
V9 IgG detection were disputed (38) and work was completed 
to resolve this significant issue (39). Resultant data, from analysis 
of blinded specimens using microplates coated with various com-
binations of parvovirus antigens (again blinded), confirmed that 
B19 VP2 capsids can indeed detect all V9-derived IgG, a finding 
which confirms the diagnostic utility of this validated immunoas-
say system for all B19 IgG detection (35). Moreover, the find-
ings of Parsyan et al. (39) made it clear that the use of the VP2 
capsid facilitates optimal antibody detection and that the addi-
tional presence of the VP1 protein did not improve diagnostic 
accuracy. In separate studies, all three erythrovirus genotypes 
were shown to both haemagglutinate human red cells and infect 
myeloid cells (KU812Ep6 or UT7/EpoS1 cells) with equal effi-
ciency leading to the conclusion that the three virus genotypes 
belong to the same species – parvovirus B19 (4). Moreover, util-
isation of erythrovirus genotype 1 capsids enabled detection of 
IgG from genotype 2-infected individuals (n = 25) and erythrovi-
rus genotype 2 capsids detected IgG from genotype 1-infected 
individuals (n = 24) (4).
Thus, it can be concluded that present data support the util-
ity of B19 immunoassay systems to efficiently detect both geno-
type 2 and genotype 3 IgM and IgG, respectively.
In the absence of robust cell culture methods to detect B19 in 
test specimens, alternative techniques can be used to both con-
firm B19 IgG detection and immune status. One such technique 
is determination of the B19-specific memory B-cell population in 
the patient and a memory B-cell ELISpot technique has been 
developed for this application (44–46) (Fig. 2).
 Isolate peripheral blood mononuclear cells (PBMCs) by density 
gradient centrifugation as follows:
 1. Pipette Histopaque-1077 (20 mL) into each of three sterile 
50 mL conical centrifuge tubes.
 2. After collecting 60 mL blood in heparinised tubes, slowly 
layer 20 mL blood on top of each Histopaque layer. Maintain 
centrifuge tubes at a 45° angle and allow specimens to run 
down side of tube until it fills to the 40 mL mark.
 3. Centrifuge specimens at 1,000 × g for exactly 30 min at room 
temperature (25°C), then carefully remove the tubes from 
the centrifuge so that the gradient is not disturbed.
 4. Using a sterile pipette, slowly aspirate the upper layer (plasma) 
to within 0.5–1 cm from the opaque interface containing the 
PBMC.
3.2.  B-Cell Memory
3.2.1. Isolation of PBMC 
and Stimulation of Cells
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 5. With a sterile transfer pipette, carefully transfer the opaque 
interface (Buffy layer) to a fresh 50 mL conical tube, avoiding 
carryover of the lower clear layer (Histopaque). The interface 
(containing PBMC) from all three tubes can be pooled into 
one 50 mL conical tube for washing.
 6. Wash PBMC with RPMI medium at room temperature and 
mix gently by inversion. Following centrifugation at 250 × g 
at room temperature for exactly 10 min, remove the superna-
tant and discard (leaving small amount of liquid at bottom). 
Using a pipette to aid in dispersion, gently resuspend the 
lymphocyte pellets in complete RPMI (12 mL). (Complete 
RPMI is prepared made up with 500 mL RPMI 1640 
Medium, 8%(v/v) heat-inactivated FCS, 100 U/mL penicil-
lin, 100 U/mL streptomycin, 2 mM l-glutamine, and 50 mM 
2-mercaptoethanol.)
 7. Conduct a cell count using a haemocytometer with approxi-
mately 10 mL of cell suspension and using a 10× microscope 
lens. A good yield is about 2.4 × 106 cells/mL (representing 1 
million cells/mL whole blood).
 8. Culture cells using a minimum of 5 × 106 cells/mL in 2 mL 
per well complete RPMI in 24-well tissue culture plates.
 9. Culture PBMC (5 × 106 cells/mL) for 5 days in complete 
RPMI in the presence of heat-killed Staphylococcus aureus cells 
(Cowan I strain) (SAC) diluted 1:5,000 and 10 ng/mL inter-
leukin-2 (IL-2). SAC and IL-2 jointly function to induce gen-
eralised antibody production in resting memory B cells (46).
Fig. 2. B-cell ELISpot using PBMC from a B19 seropositive and seronegative blood donor. Plasma from the seropositive 
donor was strongly reactive against conformational epitopes of capsid VP2 (VP2-N) and linear epitopes of VP1 (VP1-D). 
No memory B-cells were detectable against linear epitopes of VP2 (VP2-D). Distinct ELISpot wells were coated with anti-
human IgG as a positive control to verify B-cell stimulation. All incubations with PBMC at 6 × 106 cells/mL (in triplicate).
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 10. Coat nitrocellulose-lined plates (96 well) with either native B19 
VP2 (10 mg/mL), denatured VP2 (10 mg/mL), denatured 
VP1 (10 mg/mL), or rabbit anti-human IgG (10 mg/mL) in 
50 mM sodium carbonate buffer pH 9.6, overnight at 4°C.
 11. Wash ELISpot plates with sterile phosphate-buffered saline 
(PBS) and block with sterile 20%(v/v) FCS in RPMI 
medium.
 12. Add PBMC (post-stimulation) at concentrations of 1 × 106, 
1 × 105, and 1 × 104 cells/well to the plates and incubate in 
complete RPMI for 18 h at 37°C (100 mL per well).
 13. Wash ELISpot plates with PBS (4 × 200 mL per well) to 
remove unbound cells.
 14. Detect memory B cells (secreted IgG) by incubation with 
biotinylated rabbit anti-human IgG (1 mg/mL in (1% (w/v) 
BSA in PBS)), for 1 h at room temperature, followed by PBS 
washing (4 × 200 mL per well).
 15. Add streptavidin-conjugated alkaline phosphatase at a dilu-
tion of 1/1,000 (1% (w/v) BSA in PBS) and incubate for 1 h 
at room temperature, followed by PBS washing (4 × 200 mL 
per well).
 16. Addition of 5-bromo-4-chloro-3-indolyl phosphate/(nitro 
blue tetrazolium (BCIP/NBT) substrate (100 mL per well) 
facilitates memory B cell detection as spots. This develop-
ment step proceeds for 15 min after which spots can be 
counted under light microscopy (Fig. 2).
 17. The number of spots are averaged from triplicate wells and 
resultant data reported as the mean number of spot-forming 
cells (SFC)/million starting cells (44).
 1. Isolate peripheral blood mononuclear cells (PBMC) from indi-
viduals by density gradient centrifugation as described in 
Subheading 3.2.1.
 2. Culture PBMC (2 × 106 cells/mL) in triplicate with purified 
recombinant VP1 (10 mg/mL) or VP2 (10 mg/mL) for 72 h 
(previously 0.2 mm filtered). Optional: parallel cultures can be 
set up for (a) proliferation assays and (b) cytokine analysis 
from cell culture supernatants.
 3. Cells cultured with medium alone or with a combination of 
phytohemagglutinin (PHA; 2 mg/mL) serve as negative and 
positive controls, respectively.
 4. Add 0.5–1 mCi of [3H]-Thymidine for the final 4 h of culture, 
to facilitate labelling of cells, before harvesting onto glass 
fibre filters using automatic cell harvesting.
 5. Liquid scintillation counting (LCS) is carried out using 5 mL 
LCS fluid per glass fibre filter. Background values for negative 
3.3. B19 T-Cell 
Proliferation Assays 
and Cytokine 
Detection
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control samples are typically between 200 and 600 cpm, and 
always less than 1,500 cpm. Results are expressed as stimula-
tion indices (S.I.) representing the proliferative response for 
test samples divided by the response obtained from the nega-
tive controls.
 6. IL-2, IL-10, IL-13, IFN-g, and other cytokines can, in paral-
lel cell culture supernatants, be assayed by commercially avail-
able ELISA with pg/mL sensitivity of detection or IFN-g 
ELISpot (35, 47–50).
The main technique used for B19 detection is PCR and many 
groups have described both qualitative and quantitative PCR 
strategies for detection of individual, or all three, B19 genotypes 
(51–54). Apart from total genotype detection, the balance 
between PCR assay sensitivity and specificity to facilitate detec-
tion of acute infection only is important (2).
 1. Obtain stock proteinase K and dilute to 20 mg/mL, or prepare 
stock proteinase K (20 mg/mL) by resuspending in either 
25 mM Tris–HCl or sterile high purity water.
 2. Obtain clinical specimens (ideally serum or plasma) and add 
2 mL proteinase K (20 mg/mL) per 100 mL, mix by gentle 
vortexing and incubate at 56°C for 1 h. Specimens can be 
pre-diluted (10−4–10−10) in phosphate-buffered saline (PBS) 
prior to proteinase K digestion to facilitate semi-quantitative 
B19 DNA titre evaluation.
 3. After incubation, boil all treated specimens at 100°C for 
5 min to inactivate proteinase K and centrifuge (13,000 × g 
for 30 min at 4°C) to remove precipitated protein. It should 
be noted that biological specimens (plasma, amniotic fluid or 
soft tissue) can also be extracted using the Qiagen QiAmp 
Blood kit, or similar DNA extraction kits, as described by the 
relevant manufacturer.
 4. Add template DNA (5 mL), present in each specimen super-
natant, to the following mixture: 10 mM Tris–HCl pH 9.0, 
50 mM KCl, 0.1%(v/v) Triton X-100, 2.0 mM MgCl2, 
200 mM of each dNTP, 1 M betaine, 1.0 mM of each oligo-
nucleotide primer (Table 2 (54)), specific for regions within 
the NS1 coding region of the B19 genome, and 1.25 U of 
Taq polymerase in a total volume of 50 mL.
 5. PCR amplification uses the following programme: 95°C for 
6 min, followed by 35 cycles of 95°C for 1 min, 55°C for 
1 min and 72°C for 2 min terminating in 72°C for 5 min.
 6. 10 mL of each PCR product is then subjected to 1% (w/v) 
agarose gel electrophoresis containing 0.5 mg/mL of ethidium 
bromide for 30 min at 100 V. Amplicon (202 bp) visualisation 
3.4. Nucleic Acid 
Testing
3.4.1. Specimen 
Preparation and B19 DNA 
Amplification (See Note 1 )
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can be performed using an Eagle-Eye II gel documentation 
system (Stratagene, CA, USA) or similar instrument.
 7. This assay can detect at least 200 IU B19 DNA (4 × 104 IU/mL) 
(23) and sensitivity can be further improved by use of PCR-
ELISA detection (54).
At present, two commercial quantitative B19 PCR assays are 
available, namely the Artus Parvo B19 PC Kit (http://www.qia-
gen.com) and the Lightcycler® Parvovirus B19 Quantification Kit 
(http://molecular.roche.com). According to the manufacturers, 
both systems operate at high sensitivity and specificity of detec-
tion and the Artus Parvo B19 PC Kit is capable of detecting all 
three genotypes of parvovirus B19. However, at least one non-
commercial, quantitative B19 PCR assay has been extensively 
validated for detection of B19 DNA (51) and further evaluated 
and optimised to detect all three genotypes (52). Details of these 
non-commercial assays, which amplify a 113-bp fragment in the 
VP1 region, are presented herewith:
 1. Primers: 5¢-GACAGTTATCTGACCACCCCCA-3¢ (for-
ward) and 5¢-GCTAACTTGCCCAGGCTTGT-3¢ (reverse).
 2. Target specific probe (5¢-FAM (6-carboxyfluorescein)-labelled 
and 3¢-TAMRA (6-carboxytetramethylrhodamine) (quencher)): 
5¢-CCAGTAGCAGTCATGCAGAACCTAGAGGAGA-3¢.
 3. PCR conditions: 7 mM MgCl2; 200 mM dATP, dCTP and 
dGTP; 400 mM dUTP; 300 nM each primer; 100 nM 
probe; 0.01 U Amperase and 0.025 U AmpliTaq Gold 
DNA polymerase.
 4. Template, 10 mL extracted DNA, resulting in a total volume 
of 50 mL.
 5. Amplification: 50°C for 2 min, followed by 95°C for 10 min 
and subsequently 45 cycles at 95°C for 15 s and annealing 
and extension at 58°C for 1 min (51).
An internal control probe can also be used (51)
or
3.4.2. Quantitative 
Detection of Genotypes 
1–3
Table 2 
PCR primers for high sensitivity, single-round amplification  
of parvovirus B19 (53, 54)
Primers                   Gene Position Sequence 5¢–3¢
F1 NS1 1399–1422 AATACACTGTGGTTTTATGGGCCG
R1 NS1 1600–1576 CTAAAATGGCTTTTGCAGCTTCTAC
These primers do not efficiently amplify either genotype 2 or 3 due to base-pair mismatch
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Amplification: 95°C for 15 min and subsequently 45 cycles at 
95°C for 15 s and annealing and extension at 60°C for 1 min 
(52). These authors further showed that reduction of anneal-
ing/extension temperature to 56°C contributed to an 
improvement in the detection of genotype 3 isolates.
 6. Amplification and detection can be carried out using the ABI 
Prism 7700 Sequence Detection System (51) or Lightcycler® 
instrument (52). In addition, Baylis et al. (52) modified the 
original B19 PCR assay to function with Sybr Green I (60°C 
(using a commercial Lightcycler Faststart DNA MasterPLUS 
SYBR green I kit) and a Lightcycler instrument and found 
concordance between genotype detection using the above 
primers.
A limited number of reports have appeared in the literature which 
describe cell culture conditions that facilitate B19 replication and 
the ability of B19 IgG to diminish virus infectivity (55–57). 
Although excellent research methodologies, to date, these methods 
have not gained widespread applicability for B19 antigen detection 
in routine diagnostic laboratories. Consequently, two alternative 
technologies have been proposed to detect B19 antigen in human 
serum and plasma, namely (a) B19 antigen detection immunoas-
says (17, 20) and (b) a red blood cell agglutination assay termed 
receptor-mediated haemagglutination assay (RHA) (18, 19). Since 
the latter system (i.e. RHA) occasionally fails to detect B19 antigen 
in the presence of B19 IgG, thereby producing false negativity, it 
will not be further discussed.
However, B19 antigen assays have been shown to be easy to 
perform and, in addition, one assay is capable of detecting all 
three genotypes of human parvovirus B19. Moreover, combined 
B19 antigen and IgM detection in clinical specimens by a B19 
antigen assay and a B19 IgM assay facilitated the identification of 
91% of acute B19 infections in a test population (17). This B19 
antigen detection strategy is presented in Subheading 3.5.1.
 1. Dilute test plasma and control specimens (1 in 5) in a low pH 
proprietary commercial diluent (Biotrin International Ltd., 
Dublin, Ireland) and add to IgG [anti-B19 VP2] sensitised 
microwells (100 mL/well) for 1 h.
 2. Following a wash step (4× PBST), rabbit IgG [anti-B19 
VP2]-horseradish peroxidase conjugate is incubated in the 
wells for 30 min.
 3. Following a further wash step (4× PBST), add TMB substrate 
(100 mL/well) to the microwells for 30 min.
 4. Terminate the reaction using 1 N sulphuric acid (100 mL/well) 
and measure absorbance at 450/630 nm.
3.5. Detection of B19 
Viral Antigen
3.5.1. B19 Antigen ELISA
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 5. The presence of B19 antigen in a specimen is determined by the 
absorbance ratio of specimen sample to cut-off calibrator speci-
men (Index value). Specimens which yield index values ³1.0 are 
classed positive while those £1.0 are deemed negative.
Immunohistochemistry is perhaps the least frequently used tech-
nique to detect parvovirus B19 as it requires extensive optimisa-
tion. It is also dependent on many factors such as tissue type or 
source, previous tissue treatment, available instrumentation and 
most significantly, the quality of anti-parvovirus B19 antibody 
utilised for virus detection. Consequently, the procedure pre-
sented below reflects the strategies deployed by numerous authors 
to detect parvovirus B19 in paraffin-embedded tissue sections 
using immunohistochemical techniques (58–64).
 1. Paraffin-embedded tissue sections can be dewaxed as follows: 
Immerse in xylene (60°C, 10 min, twice) followed by 5 min 
sequential immersions, two per treatment, in absolute etha-
nol, 95%(v/v) ethanol and distilled water (30 s) at room 
temperature.
 2. Block endogenous peroxidase activity by immersion of slides 
in 3% (v/v) hydrogen peroxide in distilled water, with gentle 
stirring for 30 min at room temperature.
 3. Remove residual hydrogen peroxide by gentle rinsing in dis-
tilled water.
 4. To facilitate antigen retrieval, heat slides at 96°C for 30 min 
in 10 mM sodium citrate pH 6.0 and then cool to room tem-
perature for 20 min.
 5. Immerse in TBST (0.1 M Tris–HCl, 0.2 M NaCl, and 0.05% 
(v/v) Tween 20, pH 7.4), twice, and cover with blocking 
solution (1% (w/v) skim milk powder, 1% (w/v) BSA in TBS) 
and incubate in a humidified chamber for 1 h at 37°C.
 6. Immerse slides in optimised polyclonal rabbit IgG [anti-B19] 
antibody solution (DAKO; 1/50–1/300) (58–60) and incu-
bate in a humidified chamber for 16 h at 4°C.
 7. Wash slides twice in TBS, for 5 min on each occasion and 
probe using the appropriate secondary antibody–enzyme 
conjugate and precipitating substrate (e.g. 3,3′-diaminoben-
zidine (DAB)) detection system.
 8. Ensure appropriate using of negative control sera to ensure 
validity of observed results.
Other anti-parvovirus B19 antibody preparations have been 
used for immunohistochemistry and include: (a) mouse mono-
clonal IgG [anti-VP1/VP2] from Dade Behring, Marburg, 
Germany) (61), (b) mouse monoclonal IgG [anti-VP2] from 
Chemicon International, USA (62) and (c) parvovirus B19 
3.6. Immuno-
histochemical 
Detection of B19
227The Detection of Parvoviruses
primary antibody (code R92F6; NCL-Parvo, Novocastra, 
Newcastle upon Tyne, UK) (63).
Seventeen PCR protocols for HBoV DNA detection, deploying a 
range of primer pairs and detection strategies, have recently been 
reviewed and described (26). More recently, the relative sensitivi-
ties of conventional vs. quantitative PCR have been compared 
(27). These authors describe a primer set comprising: Fwd primer 
5¢-TGGCTACACGTCCTTTTGAACC-3¢ and Rev primer 
5¢-GACTTCGTTATCTAGGGTTGCG-3¢ using the following 
PCR reaction mixture and amplification conditions:
DNA extract (4 mL), 5 mL 10× PCR buffer, 400 mM of each 
dNTP, 1 mL Taq polymerase, primers (10 pM each) in 
nuclease-free water to 50 mL.
PCR: 95°C for 15 min, 35 cycles of amplification (94°C for 
30 s; 55°C for 30 s and 72°C for 30 s) plus a final exten-
sion step at 72°C for 10 min.
Choi et al. (27) demonstrated that this PCR assay yielded a PCR 
product of 384 bp and was approximately two logs less sensitive 
than a real-time PCR assay described in the same publication, none-
theless, the aforementioned conventional HBoV PCR assay repre-
sents a useful starting point for initial forays in HBoV detection.
A quantitative PCR assay utilising consensus primers to amplify a 
region of ORF2 of PARV4 and PARV5, which is highly conserved 
between the two genotypes, has been developed (31, 32).
Fwd: 5¢-CTAAGGAAACTGTTGGTGATATTGCT-3¢ located 
between nucleotides 3285 and 3310 of ORF2 (GenBank 
Accession Number AY622943).
Rev: 5¢-GGCTCTCCTGCGGAATAAGC-3¢ located between 
nucleotides 3368 and 3387 of ORF2.
These primers amplify a 103-bp product.
Probe 5¢-(FAM) TGTTCAACTTTCTCAGGTCCTACCGCCC 
(TAMRA)-3¢) which hybridises to nucleotides 3313–
3340 of ORF2.
Amplification reaction mixture: 1× QuantiTect Probe (Qiagen, 
Germany) PCR master mix, 10 pmol of each primer, 0.05 mM of 
probe, and 5 mL of template DNA. Final volume: 20 mL. Amplifi-
cation conditions: 95°C for 15 min and then 45 cycles of 95°C 
for 15 s and 60°C for 1 min.
Extensive primer details and PCR conditions for PARV4 and 
5 detection have also been presented elsewhere (64, 65).
Standardised and validated ELISA and immunofluorescent detec-
tion systems are now commercially available to detect parvovirus 
B19 IgM and IgG resulting from exposure to all erythrovirus 
3.7. HBoV and PARV4 
Detection
3.7.1. HBoV PCR
3.7.2.  PARV4 PCR
3.8. Concluding 
Remarks
228 Doyle
genotypes. Validated molecular assays are also available to 
accurately detect viral DNA. In addition, WHO International 
Standards are now in place and enable inter-laboratory standardi-
sation of B19 IgG and DNA detection. Furthermore, a battery of 
cellular, immunohistochemical and infectivity assays can facilitate 
ongoing research into B19 pathogenicity. Although numerous 
validated research assays have been developed to detect HBoV, 
PARV4, or 5 DNA or antibody responses (HBoV only), no com-
mercial tests are yet available; however, it is clear that many of the 
lessons learned from B19 assay development will find resonance 
in future studies on, and detection systems for, these emerging 
pathogens.
 1. DNA extraction should always be performed in separate labo-
ratory to that of PCR reagent preparation and nucleic acid 
amplification.
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